Search results for "Bioinformatics"

showing 10 items of 1632 documents

PML risk stratification using anti-JCV antibody index and L-selectin

2015

Background: Natalizumab treatment is associated with progressive multifocal leukoencephalopathy (PML) development. Treatment duration, prior immunosuppressant use, and JCV serostatus are currently used for risk stratification, but PML incidence stays high. Anti-JCV antibody index and L-selectin (CD62L) have been proposed as additional risk stratification parameters. Objective: This study aimed at verifying and integrating both parameters into one algorithm for risk stratification. Methods: Multicentric, international cohorts of natalizumab-treated MS patients were assessed for JCV index (1921 control patients and nine pre-PML patients) and CD62L (1410 control patients and 17 pre-PML patient…

0301 basic medicineOncologymedicine.medical_specialtyMultiple SclerosisvirusesMedizinOpportunistic InfectionsAntibodies ViralBioinformaticsRisk AssessmentImmunocompromised Host03 medical and health sciences0302 clinical medicineNatalizumabRisk FactorsInternal medicineHumansMedicineSerologic TestsL-SelectinRisk factorRetrospective Studiesbusiness.industryNatalizumabProgressive multifocal leukoencephalopathyMultiple sclerosisIncidence (epidemiology)Leukoencephalopathy Progressive Multifocalvirus diseasesmedicine.diseaseJC VirusEuropeTreatment Outcome030104 developmental biologyNeurologyRelative riskBiomarker (medicine)Neurology (clinical)businessSerostatusAlgorithmsBiomarkers030217 neurology & neurosurgerymedicine.drugMultiple Sclerosis Journal
researchProduct

Developmental transcriptomics in Atlantic haddock: Illuminating pattern formation and organogenesis in non-model vertebrates.

2016

Gadiforms such as Atlantic haddock comprise some of the world's most economically important fisheries. Understanding the early life history of these fish is a prerequisite for predicting effects of a changing environment and increased human activities. Robust assessment of the effects of environmental impacts on the embryos of non-model vertebrates is hampered by a lack of molecular resources and detailed knowledge regarding the regulation of genes and pathways in early development. Here we used mRNA sequencing to link transcriptional changes to developmental processes in haddock, specifically, pattern formation and organogenesis. Temporal expression of key developmental genes was tightly a…

0301 basic medicineOrganogenesisved/biology.organism_classification_rank.speciesOrganogenesisBioinformaticsEyeCardiovascular SystemBone and BonesTranscriptome03 medical and health sciences0302 clinical medicinebiology.animalAnimalsRNA MessengerModel organismMolecular BiologyBody PatterningGene Librarybiologyved/biologySequence Analysis RNAGene Expression ProfilingSkullFishesVertebrateComputational BiologyGene Expression Regulation DevelopmentalCell BiologyHaddockBlastulaBlastulabiology.organism_classificationGene expression profiling030104 developmental biologyMRNA SequencingEvolutionary biologyLarvaTranscriptome030217 neurology & neurosurgeryDevelopmental BiologyDevelopmental biology
researchProduct

Exosomal microRNAs in liquid biopsies: future biomarkers for prostate cancer

2017

Abstract: Prostate cancer is the second most diagnosed cancer in males in the world. Plasma quantification of prostate-specific antigen substantially improved the early detection of prostate cancer, but still lacks the required specificity. Clinical management of prostate cancer needs advances in the development of new non-invasive biomarkers, ameliorating current diagnosis and prognosis and guiding therapeutic decisions. microRNAs (miRNAs) are a class of small non-coding RNAs that regulate gene expression at the post-transcriptional level. These miRNAs are expressed in the cells and are also present in cell-derived extracellular vesicles such as exosomes. Exosomes have been shown to act as…

0301 basic medicinePCA3MaleCancer ResearchBiomarker; Exosome; Liquid biopsies; MiRNAs; Prostate cancerBioinformaticsExosomesExosome03 medical and health sciencesProstate cancer0302 clinical medicineProstateLiquid biopsiemicroRNABiomarkers TumorMedicineHumansLiquid biopsyProstate cancerbusiness.industryLiquid BiopsyCancerProstatic NeoplasmsGeneral MedicineBiomarkermedicine.diseaseMicrovesiclesExosomeMicroRNAs030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchHuman medicinebusinessMiRNA
researchProduct

Parkinson's disease: towards better preclinical models and personalized treatments.

2016

Non peer reviewed

0301 basic medicineParkinson's diseaseeducationMEDLINEBioinformatics03 medical and health sciencesCellular and Molecular Neuroscience0302 clinical medicineDEFICITSMedicineAnimalsHumansMolecular BiologyPharmacologybusiness.industryParkinson DiseaseCell Biologymedicine.diseaseMolecular medicine3. Good healthMICE030104 developmental biologyNeuroprotective AgentsCell Biology; Molecular Biology; Molecular Medicine; Pharmacology; Cellular and Molecular NeuroscienceMolecular Medicine3111 Biomedicinebusiness030217 neurology & neurosurgeryCellular and molecular life sciences : CMLS
researchProduct

Toll-like receptor-4 signaling pathway in aorta aging and diseases: “its double nature”

2017

Recent advances in the field of innate immunity have revealed a complex role of innate immune signaling pathways in both tissue homeostasis and disease. Among them, the Toll-like receptor 4 (TLR-4) pathways has been linked to various pathophysiological conditions, such as cardiovascular diseases (CVDs). This has been interrogated by developing multiple laboratory tools that have shown in animal models and clinical conditions, the involvement of the TLR-4 signaling pathway in the pathophysiology of different CVDs, such as atherosclerosis, ischemic heart disease, heart failure, ischemia-reperfusion injury and aorta aneurysm. Among these, aorta aneurysm, a very complex pathological condition w…

0301 basic medicinePathologymedicine.medical_specialtyAgingDisease030204 cardiovascular system & hematologyBioinformatics03 medical and health sciences0302 clinical medicineAneurysmAorta; Aorta aneurysms; TLR-4 signaling pathway; Treatments; Aging; Animals; Aorta; Cardiovascular Diseases; Homeostasis; Humans; Toll-Like Receptor 4; Signal TransductionAorta aneurysmsmedicine.arterymedicineSettore MED/05 - Patologia ClinicaAnimalsHomeostasisHumansMolecular BiologyTissue homeostasisAortaToll-like receptorAortaAorta; Aorta aneurysms; TLR-4 signaling pathway; TreatmentsInnate immune systembusiness.industryTreatmentsTLR-4 signaling pathwaySettore MED/23 - Chirurgia Cardiacamedicine.diseaseToll-Like Receptor 4030104 developmental biologyCardiovascular DiseasesHeart failurecardiovascular systemAorta aneurysmSignal transductionCardiology and Cardiovascular MedicinebusinessSignal Transduction
researchProduct

A "systems medicine" approach to the study of non-alcoholic fatty liver disease

2016

a b s t r a c t The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diag- nosis criteria, and new endpoints of clinical trials).…

0301 basic medicinePathologymedicine.medical_specialtyFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Gastroenterology; HepatologySystems AnalysisSystems biologyPersonalizedPopulationDiseaseBioinformatics03 medical and health sciences0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsInternal medicineFatty liverNAFLDFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicinemedicineHumansFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Hepatology; GastroenterologyeducationFatty liver; Medicine; NAFLD; NASH; Personalized; Systems medicine; Disease Progression; Humans; Non-alcoholic Fatty Liver Disease; Phenotype; Risk Factors; Systems Biology; Systems Analysis; Medicine (all); Hepatology; Gastroenterologyeducation.field_of_studyHepatologybusiness.industrySystems BiologySettore MED/09 - MEDICINA INTERNAFatty liverGastroenterologyNASHHepatologymedicine.diseaseSystems medicineClinical trial030104 developmental biologyPhenotypeSystems medicineDisease ProgressionMedicine030211 gastroenterology & hepatologySteatosisbusiness
researchProduct

Cystic fibrosis treatment: targeting the basic defect

2017

ABSTRACTIntroduction: Cystic Fibrosis (CF) is a disease caused by different class mutations in the CF transmembrane conductance regulator (CFTR) gene. It can therefore benefit from a personalized medicine approach based on the individual genotype of each patient.Areas covered: This review provides a detailed overview of the current major development of new CF treatments that target the basic CF defect. The review summarizes gene therapy, mRNA repair strategies, read-through agents, and CFTR-modulators (potentiators, correctors, stabilizers, amplifiers and different combination therapies).Expert opinion: We are currently perhaps at the most exciting stage in the history of CF, with the poten…

0301 basic medicinePathologymedicine.medical_specialtyMutationCombination therapybusiness.industryHealth PolicyGenetic enhancementDiseasePotentiatorBioinformaticsmedicine.diseasemedicine.disease_causeCystic fibrosisIvacaftor03 medical and health sciences030104 developmental biology0302 clinical medicine030228 respiratory systemMedicinePharmacology (medical)Personalized medicinebusinessPharmacology Toxicology and Pharmaceutics (miscellaneous)medicine.drugExpert Opinion on Orphan Drugs
researchProduct

Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease

2016

International audience; Neurodegenerative diseases are a major public health issue worldwide. Some countries, including France, have engaged in research into the causes of Parkinson's disease, Alzheimer's disease, and multiple sclerosis and the management of these patients. It should lead to a better understanding of the mechanisms leading to these diseases including the possible involvement of lipids in their pathogenesis. Parkinson's disease is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra and the accumulation of α-synuclein (Lewy bodies). Several in vivo studies have shown a relationship between the lipid profile [chole…

0301 basic medicinePathologymedicine.medical_specialtyParkinson's diseaseOxysterolParkinson's diseasePresynaptic TerminalsSubstantia nigraDiseaseBiologyBioinformaticsBiochemistryPathogenesisProtein Aggregates03 medical and health scienceschemistry.chemical_compoundOxysterol0302 clinical medicinePhysiology (medical)medicineHumans[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyAlpha-synucleinCell Deathmedicine.diagnostic_testDopaminergic NeuronsMultiple sclerosisParkinson DiseaseOxysterols[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismmedicine.diseaseSubstantia NigraCholesterol030104 developmental biologychemistryalpha-Synucleinlipids (amino acids peptides and proteins)Lipid profileOxidation-Reduction030217 neurology & neurosurgeryFree Radical Biology and Medicine
researchProduct

eIF5A facilitates translation termination globally and promotes the elongation of many non polyproline-specific tripeptide sequences

2017

Abstract eIF5A is an essential protein involved in protein synthesis, cell proliferation and animal development. High eIF5A expression is observed in many tumor types and has been linked to cancer metastasis. Recent studies have shown that eIF5A facilitates the translation elongation of stretches of consecutive prolines. Activated eIF5A binds to the empty E-site of stalled ribosomes, where it is thought to interact with the peptidyl-tRNA situated at the P-site. Here, we report a genome-wide analysis of ribosome stalling in Saccharomyces cerevisiae eIF5A depleted cells using 5Pseq. We confirm that, in the absence of eIF5A, ribosomes stall at proline stretches, and extend previous studies by …

0301 basic medicinePeptidyl transferaseProlineCytoskeleton organizationAmino Acid MotifsSaccharomyces cerevisiaePeptide Chain Elongation TranslationalSaccharomyces cerevisiaeBioinformaticsRibosomeGTP Phosphohydrolases03 medical and health sciences0302 clinical medicinePeptide Initiation FactorsGene Expression Regulation FungalGeneticsProtein biosynthesisHumansMolecular BiologyPolyproline helixBinding SitesbiologyRNA-Binding Proteinsbiology.organism_classificationStop codonCell biology030104 developmental biologybiology.proteinGenome FungalHydrophobic and Hydrophilic InteractionsRibosomesEIF5A030217 neurology & neurosurgeryProtein BindingNucleic Acids Research
researchProduct

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk.

2016

Peroxisome proliferator-activated receptors (PPAR) are implicated in the pathology of several metabolic diseases including obesity, diabetes, and atherosclerosis. PPAR agonists exert multiple lipid modifying actions which are beneficial to the prevention of atherosclerosis. Such benefits in lipid lowering actions include improvements in atherogenic dyslipidemia that seems to be particularly expressed in individuals at higher cardiovascular (CV) risk. In addition, the favorable effects of PPAR agonists on different cardio-metabolic parameters are established in several metabolic conditions, such as diabetes mellitus, insulin resistance, and heightened systemic inflammation. The goal of this …

0301 basic medicinePeroxisome Proliferator-Activated Receptormedicine.medical_specialtyPeroxisome Proliferator-Activated ReceptorsPeroxisome proliferator-activated receptor030204 cardiovascular system & hematologyBioinformaticsSystemic inflammationPPAR agonist03 medical and health sciences0302 clinical medicineInsulin resistanceRisk FactorsCardiovascular DiseaseInternal medicineDiabetes mellitusDrug DiscoverymedicineAnimalsHumansDyslipidemiasHypolipidemic AgentsPharmacologychemistry.chemical_classificationClinical Trials as TopicHypolipidemic Agentmedicine.diagnostic_testAnimalbusiness.industryRisk FactorAtherogenic dyslipidemiaCardiovascular riskmedicine.diseaseAtherosclerosisObesityThiazoles030104 developmental biologyEndocrinologyDyslipidemiachemistryCardiovascular DiseasesAtherosclerosilipids (amino acids peptides and proteins)medicine.symptomLipid profilebusinessHumanLipoproteinCurrent pharmaceutical design
researchProduct